{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003931","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.878425+00:00","generated_at":"2026-06-28T10:04:39.637486+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Finch Therapeutics Q3 2021 net loss $10.0M; CP101 Phase 2 shows 80.3% cure rate","bullets":["Net loss of $10.0M for Q3 2021 (vs. $10.1M loss in Q3 2020); R&D expenses increased to $15.5M from $9.0M.","CP101 Phase 2 open-label trial: 80.3% sustained clinical cure at 8 weeks, 78.8% at 24 weeks in recurrent CDI.","Initiated enrollment in PRISM4 Phase 3 trial of CP101; topline data expected H1 2023.","Cash and equivalents $149.2M as of Sept 30, 2021; expected to fund operations into mid-2023.","CMO Zain Kassam stepped down; Debra Silberg named interim CMO; Marc Blaustein joined as COO; Al Hamood added to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003931","json":"https://secwatch.observer/filing/0000950170-21-003931.json","markdown":"https://secwatch.observer/filing/0000950170-21-003931.md","text":"https://secwatch.observer/filing/0000950170-21-003931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017021003931/0000950170-21-003931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017021003931/fnch-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:04:39.637486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}